BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $10
Recursion Pharmaceuticals Price Target Lowered to $10 From $12 at BofA
Recursion to Present at 43rd Annual JP Morgan Healthcare Conference
Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer
Cathie Wood's Ark Invest Books Profits On Hot AI Stock Palantir, Sells Bitcoin ETF Shares As BTC Starts 2025 On A Positive Note
Trending Industry Today: Serve Robotics Leads Gains In NVIDIA Portfolio Stocks
